AMED stock icon

Amedisys
AMED

$91.82
0.15%
 

About: Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.

Employees: 19,000

0
Funds holding %
of 6,689 funds
Analysts bullish %
0
News positive %
of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

2% less funds holding

Funds holding: 281 [Q4 2023] → 274 (-7) [Q1 2024]

4.1% less ownership

Funds ownership: 94.36% [Q4 2023] → 90.26% (-4.1%) [Q1 2024]

7% less capital invested

Capital invested by funds: $2.93B [Q4 2023] → $2.72B (-$209M) [Q1 2024]

18% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 40

23% less funds holding in top 10

Funds holding in top 10: 13 [Q4 2023] → 10 (-3) [Q1 2024]

24% less repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 112

85% less call options, than puts

Call options by funds: $12.5M | Put options by funds: $81.2M

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$100
9%
upside
Avg. target
$101
9%
upside
High target
$101
10%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
Cantor Fitzgerald
Sarah James
10%upside
$101
Neutral
Reiterated
25 Apr 2024
RBC Capital
Ben Hendrix
9%upside
$100
Outperform
Maintained
25 Mar 2024

Financial journalist opinion

Based on 3 articles about AMED published over the past 30 days